Brought to you by:
VOYAGER PAD: Rivaroxaban plus aspirin versus aspirin alone among CLTI patients undergoing revascularization reduced risk of adverse outcomes at three years
In one of the latest sub-analyses from the VOYAGER PAD trial, investigators found that rivaroxaban plus aspirin versus aspirin alone in the high-risk population of patients with critical limb-threatening ischemia (CLTI) undergoing lower-extremity revascularization reduced the risk of a first…
Previously described patient-centered clinical success measure after revascularization for diabetic foot wounds may be ‘too strict’
Patient-centered clinical success after lower-extremity revascularization for people with diabetic foot wounds was achieved among 63% of patients in a new analysis—but researchers suggest the measure on which the study was based may define clinical success too strictly given the…
Intravascular lithotripsy ‘superior’ to PTA in acute procedural success out to 30 days
The DISRUPT PAD III randomized controlled trial (RCT) provides the largest level-one evidence for the treatment of heavily calcified femoropopliteal arteries, noted William Gray, MD, an interventional cardiologist at Main Line Health, Philadelphia, during the second and final late-breaking data…
Latest VOYAGER PAD analysis finds no mortality and improved limb outcomes in drug-coated device cohort
Given the absence of a safety signal in data from the VOYAGER PAD trial, a new analysis examined the potential benefit of drug-coated device versus non-drug-coated device treatment for reducing limb outcomes. Connie Hess, MD, an associate professor of cardiology…
Utilize new SVS Branding Toolkit
The new SVS Branding Toolkit—a robust set of tools designed to help members communicate their roles in comprehensive vascular care—is now available exclusively and at no cost to members of the Society for Vascular Surgery (SVS). Additionally, most are customizable…
Janssen applies to FDA for new indication to expand use of rivaroxaban in PAD patients
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the Food and Drug Administration (FDA) for a new indication to expand the use of Xarelto (rivaroxaban) in patients with…
New analysis finds DCBs lead to greater four-year survival after fempop revascularization
Patients treated with a paclitaxel-coated balloon saw greater survival, freedom from amputation and amputation-free survival through four-year follow-up after their initial femoropopliteal revascularization operation than those who received treatment using an uncoated device, researchers behind a propensity-matched retrospective review at…
Hodgson: Bringing appropriateness into sharper focus
In 2019, Kim Hodgson, MD, kicked off his presidential year by placing appropriateness and quality of care under the microscope. His turn organizing the E. Stanley Crawford Critical Issues Forum at the 2019 Vascular Annual Meeting (VAM) saw the then…
VA system delivers high quality services for veterans
Vascular surgery in the Veterans Health Administration has always been a robust service, developing into a mature specialty around the time of the Vietnam conflict. Over the years, many have called into question the quality of care within the Veterans…
‘No signal of increased risk of long-term mortality’ with paclitaxel-coated Luminor DCB, EffPac trial finds
An ad hoc, two-year analysis of the EffPac study found no signal of increased risk of long-term mortality, nor any adverse events, within two years of drug-coated balloon (DCB) angioplasty using a Luminor-35 device (iVascular). This was the conclusion presented by…